ArticleNanomedicine : nanotechnology, biology, and medicine2019
Tumor selective uptake of drug-nanodiamond complexes improves therapeutic outcome in pancreatic cancer.
Article in Nanomedicine : nanotechnology, biology, and medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 41 citations in OpenAlex.
- Tumor Spheroid Uptake of Fluorescent Nanodiamonds Is Limited by Mass Density: A 4D Light-Sheet Assay.Chemical & biomedical imaging · 2025Article
- Three-Dimensional In Vitro Tumor Spheroid Models for Evaluation of Anticancer Therapy: Recent Updates.Cancers · 2023Review
- (Nano)platforms in bladder cancer therapy: Challenges and opportunities.Bioengineering & translational medicine · 2023Review
- Preclinical PET and MR Evaluation ofNanomaterials (Basel, Switzerland) · 2022Article
- Effects of Carbon Nanomaterials andPharmaceutics · 2022Review
- Nanoscale Diamond-Based Formulation as an Immunomodulator and Potential Therapeutic for Lymphoma.Frontiers in pharmacology · 2022Article
- Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4.International journal of nanomedicine · 2021Article
- Drug Delivery Systems of Natural Products in Oncology.Molecules (Basel, Switzerland) · 2020Review
- Review
- Therapeutic Nanoparticles and Their Targeted Delivery Applications.Molecules (Basel, Switzerland) · 2020Review
- Why nanodiamond carriers manage to overcome drug resistance in cancer.Cancer drug resistance (Alhambra, Calif.) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related deaths and novel treatment approaches are urgently needed. Here we show that poly(ethylene glycol)-functionalized nanodiamonds loaded with doxorubicin (ND-PEG-DOX) afforded a considerable improvement over free drug in an orthotopic pancreatic xenograft model. ND-PEG-DOX complexes were also superior to free DOX in 3-dimensional (3D) tumor spheroids of PDAC. ND-PEG showed no cytotoxicity towards macrophages, and histopathological analysis showed no abnormalities of major organs upon in vivo administration of ND-PEG-DOX. These results provide evidence that ND-mediated drug delivery may serve as a means of improving the therapeutic outcome in PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.